Loading...
HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
BACKGROUND: Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low‐density lipoprotein cholesterol (LDL‐C) and improve outcomes in the general population. HIV‐infected individuals are at increased risk for cardiovascular events and have high rates of dyslipidemia and hepatitis C viru...
Saved in:
| Published in: | J Am Heart Assoc |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4889164/ https://ncbi.nlm.nih.gov/pubmed/27130349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002683 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|